Tian An Medicare Beheer

Beheer criteriumcontroles 2/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	no data
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	5.9yrs
Gemiddelde ambtstermijn bestuur	5.9yrs

Recente managementupdates

Recent updates

China Medical & HealthCare Group's (HKG:383) Returns On Capital Not Reflecting Well On The Business

Feb 02

Returns On Capital Signal Difficult Times Ahead For China Medical & HealthCare Group (HKG:383)

Oct 26

Is China Medical & HealthCare Group (HKG:383) Using Debt In A Risky Way?

Sep 30

China Medical & HealthCare Group (HKG:383) Might Have The Makings Of A Multi-Bagger

Dec 10

CEO

Tian An Medicare heeft geen CEO, of we hebben geen gegevens over hen.

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Meibao Guo	Executive Director	6.2yrs	HK$1.60m	geen gegevens
Haiying Zhou	Executive Director	5.9yrs	geen gegevens	geen gegevens
Muk Yin Kong	Executive Director & Company Secretary	less than a year	HK$2.07m	geen gegevens

5.9yrs

Gemiddelde duur

54yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 383 is doorgewinterd en ervaren (gemiddelde ambtstermijn van 5.9 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Meibao Guo	Executive Director	6.2yrs	HK$1.60m	geen gegevens
Haiying Zhou	Executive Director	5.9yrs	geen gegevens	geen gegevens
Muk Yin Kong	Executive Director & Company Secretary	2.1yrs	HK$2.07m	geen gegevens
Tai Chun Wong	Non-Executive Director	1.1yrs	HK$34.00k	geen gegevens
Seng-Hui Lee	Non-Executive Chairman	1.1yrs	HK$34.00k	geen gegevens
Lai Sum Yang	Independent Non-Executive Director	5.9yrs	HK$150.00k	geen gegevens
Xiaoning Xia	Independent Non-Executive Director	7.9yrs	HK$150.00k	geen gegevens
Wing Kuen Wong	Independent Non-Executive Director	5.9yrs	HK$180.00k	geen gegevens
Jian Zhang	Independent Non-Executive Director	18.1yrs	HK$150.00k	geen gegevens
Zhaoyuan Gao	Non-Executive Director	2.1yrs	HK$150.00k	geen gegevens

5.9yrs

Gemiddelde duur

57.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 383 wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.9 jaar).

Tian An Medicare Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

China Medical & HealthCare Group Limited, Annual General Meeting, May 20, 2024

China Medical & Healthcare Group Limited Announces Company Secretary and Authorised Representative Changes

China Medical & HealthCare Group Limited Announces Change in the Composition of the Board of Directors and Change of Members of the Board Committees

China Medical & Healthcare Group Limited Announces Resignation of Chong Sok Un as Executive Director and Deputy Chairman and Change in Composition of the Board Committees

Less than half of directors are independent

China Medical & Healthcare Group Limited Announces Executive Changes

Recent updates

New minor risk - Market cap size

First half 2024 earnings released: EPS: HK$0.02 (vs HK$0.002 in 1H 2023)

First half 2024 earnings released: EPS: HK$0.02 (vs HK$0.002 loss in 1H 2023)

Tian An Medicare Limited to Report Q4, 2024 Results on Aug 02, 2024

Upcoming dividend of HK$0.01 per share

Full year 2023 earnings released: EPS: HK$0.012 (vs HK$0.17 loss in FY 2022)

China Medical & Healthcare Group Limited Proposes Ordinary Final Dividend for the Year Ended 31 December 2023, Payable on 02 August 2024

Full year 2023 earnings released: EPS: HK$0.012 (vs HK$0.17 loss in FY 2022)

China Medical & HealthCare Group Limited, Annual General Meeting, May 20, 2024

China Medical & HealthCare Group Limited to Report Fiscal Year 2023 Final Results on Mar 15, 2024

New minor risk - Market cap size

China Medical & Healthcare Group Limited Provides Earnings Guidance for Eleven Months Ended 30 November 2023

China Medical & Healthcare Group Limited Announces Company Secretary and Authorised Representative Changes

China Medical & HealthCare Group Limited Announces Change in the Composition of the Board of Directors and Change of Members of the Board Committees

Tian An China Investments Company Limited (SEHK:28) completed the acquisition of 18.13% stake in China Medical & HealthCare Group Limited (SEHK:383) from its shareholders for approximately HKD 180 million.

China Medical & Healthcare Group Limited Announces Resignation of Chong Sok Un as Executive Director and Deputy Chairman and Change in Composition of the Board Committees

First half 2023 earnings released: HK$0.002 loss per share (vs HK$0.061 loss in 1H 2022)

New major risk - Revenue and earnings growth

China Medical & HealthCare Group Limited to Report Second Half, 2023 Results on Aug 18, 2023

China Medical & HealthCare Group Limited Provides Group Earnings Guidance for the Five Months Ended 31 May 2023

Full year 2022 earnings released: HK$0.17 loss per share (vs HK$0.19 loss in FY 2021)

China Medical & HealthCare Group's (HKG:383) Returns On Capital Not Reflecting Well On The Business

China Medical & Healthcare Group Limited Provides Consolidated Earnings Guidance for the Eleven Months Ended 30 November 2022

Less than half of directors are independent

China Medical & Healthcare Group Limited Announces Executive Changes

Returns On Capital Signal Difficult Times Ahead For China Medical & HealthCare Group (HKG:383)

Is China Medical & HealthCare Group (HKG:383) Using Debt In A Risky Way?

First half 2022 earnings released: HK$0.003 loss per share (vs HK$0.005 loss in 1H 2021)

China Medical & HealthCare Group Limited Provides Unaudited Consolidated for the Five Months Ended 31 May 2022

Less than half of directors are independent

Full year 2021 earnings released: HK$0.009 loss per share (vs HK$0.008 loss in FY 2020)

China Medical & HealthCare Group Limited, Annual General Meeting, Jun 01, 2022

China Medical & HealthCare Group (HKG:383) Might Have The Makings Of A Multi-Bagger

First half 2021 earnings released: HK$0.005 loss per share (vs HK$0.005 loss in 1H 2020)

First half 2021 earnings released: HK$0.005 loss per share (vs HK$0.005 loss in 1H 2020)

China Medical & HealthCare Group Limited Provides Unaudited Consolidated Earnings Guidance for the Four Months Ended April 30, 2021

Executive Director has left the company

Non-Executive Director has left the company

Chairman Liye Zhou has left the company

We Think China Medical & HealthCare Group (HKG:383) Has A Fair Chunk Of Debt

China Medical & HealthCare Group Limited to Report Fiscal Year 2020 Results on Mar 30, 2021

Do Institutions Own China Medical & HealthCare Group Limited (HKG:383) Shares?

Is China Medical & HealthCare Group (HKG:383) A Risky Investment?

China Medical & Healthcare Group Limited Appoints Lai Hin Wing Henry Stephen as Non-Executive Director, Effective November 11, 2020

First half earnings released

China Medical & HealthCare Group Limited to Report 18 Months Period Ending Dec 31, 2019 Results on Mar 30, 2020

China Medical & HealthCare Group Limited to Report Second Half, 2020 Results on Aug 27, 2020

CEO

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd